Valuation: AbbVie Inc.

Capitalization 356B 302B 277B 261B 487B 33,927B 491B 3,282B 1,281B 16,158B 1,336B 1,308B 55,916B P/E ratio 2026 *
24.6x
P/E ratio 2027 * 18.3x
Enterprise value 410B 348B 319B 301B 561B 39,078B 565B 3,780B 1,476B 18,611B 1,539B 1,507B 64,405B EV / Sales 2026 *
6.1x
EV / Sales 2027 * 5.51x
Free-Float
96.03%
Yield 2026 *
3.41%
Yield 2027 * 3.59%
1 day+1.00%
1 week-2.28%
Current month-3.74%
1 month-1.48%
3 months-7.91%
6 months-9.66%
Current year-10.98%
1 week 200.02
Extreme 200.02
209.52
1 month 190.75
Extreme 190.75
214.87
Current year 190.75
Extreme 190.75
237.11
1 year 176.57
Extreme 176.57
244.81
3 years 130.96
Extreme 130.9601
244.81
5 years 105.56
Extreme 105.56
244.81
10 years 55.06
Extreme 55.0623
244.81
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Compliance Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 68 01/01/2013
Change 5d. change 1-year change 3-years change Capi.($)
+1.01%-2.28%+7.02%+38.76% 356B
+2.23%+0.41%+28.63%+123.14% 846B
+0.13%-1.14%+43.80%+37.68% 533B
+1.21%-0.97%+22.40%+12.53% 324B
+1.18%+1.29%+31.44%+13.23% 282B
+0.30%-0.12%+24.02%+22.81% 278B
+1.04%-0.35%+40.13%-4.12% 275B
+3.34%+6.03%-32.03%-48.08% 203B
-0.71%+1.71%+19.89%+41.81% 179B
+1.96%+0.87%+28.92%+70.06% 163B
Average +1.22%-0.63%+21.42%+30.78% 343.84B
Weighted average by Cap. +1.29%-1.12%+24.91%+46.59%

Financials

2026 *2027 *
Net sales 67.21B 57.04B 52.24B 49.25B 91.86B 6,404B 92.6B 619B 242B 3,050B 252B 247B 10,554B 72.61B 61.61B 56.43B 53.2B 99.23B 6,918B 100B 669B 261B 3,295B 272B 267B 11,401B
Net income 14.93B 12.67B 11.6B 10.94B 20.4B 1,422B 20.56B 138B 53.7B 677B 56B 54.83B 2,344B 19.32B 16.4B 15.02B 14.16B 26.41B 1,841B 26.62B 178B 69.51B 877B 72.5B 70.98B 3,034B
Net Debt 54.06B 45.88B 42.02B 39.62B 73.89B 5,151B 74.48B 498B 194B 2,453B 203B 199B 8,489B 44.23B 37.54B 34.38B 32.41B 60.46B 4,214B 60.94B 408B 159B 2,007B 166B 162B 6,946B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
12/05/26 203.48 $ +0.96% 1,913,776
08/05/26 201.55 $ -0.57% 4,915,719
07/05/26 202.71 $ -1.13% 6,681,070
06/05/26 205.03 $ -0.52% 7,289,987
05/05/26 206.11 $ -0.98% 4,490,528
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
201.55USD
Average target price
252.23USD
Spread / Average Target
+25.15%

Quarterly revenue - Rate of surprise